BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 2182597)

  • 1. The evolving role of bone marrow transplantation in the treatment of chronic myelogenous leukemia.
    Delage R; Ritz J; Anderson KC
    Hematol Oncol Clin North Am; 1990 Apr; 4(2):369-88. PubMed ID: 2182597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Mackinnon S; Barnett L; Heller G
    Bone Marrow Transplant; 1996 Apr; 17(4):643-7. PubMed ID: 8722369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic myelogenous leukemia with bone marrow transplantation.
    Snyder DS; McGlave PB
    Hematol Oncol Clin North Am; 1990 Jun; 4(3):535-57. PubMed ID: 2193013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
    Román J; Alvarez MA; Torres A
    Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Román J; Serrano J; Jiménez A; Castillejo JA; Reina ML; González MG; Rodríguez MC; García I; Sánchez J; Maldonado J; Torres A
    Haematologica; 2000 Feb; 85(2):173-80. PubMed ID: 10681725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: a review of recent results.
    Miyamura K; Barrett AJ; Kodera Y; Saito H
    Bone Marrow Transplant; 1994 Aug; 14(2):201-9. PubMed ID: 7994233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
    Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
    Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent donor chimaerism is consistent with disease-free survival following BMT for chronic myeloid leukaemia.
    Gardiner N; Lawler M; O'Riordan J; DeArce M; Humphries P; McCann SR
    Bone Marrow Transplant; 1997 Aug; 20(3):235-41. PubMed ID: 9257892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Indications, technique and risks in bone marrow transplantation in adulthood].
    Heyll A; Söhngen D; Minning H; Meckenstock G; Aul C; Schneider W
    Praxis (Bern 1994); 1996 Mar; 85(12):378-86. PubMed ID: 8643901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow transplantation for chronic myelogenous leukemia: clinical outcomes.
    Enright H; Davies S; McGlave P
    Clin Transpl; 1994; ():283-93. PubMed ID: 7547549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
    Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia.
    Lin F; Kirkland MA; van Rhee FV; Chase A; Coulthard S; Bungey J; Goldman JM; Cross NC
    Bone Marrow Transplant; 1996 Dec; 18(6):1147-52. PubMed ID: 8971386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression.
    Collins RH; Rogers ZR; Bennett M; Kumar V; Nikein A; Fay JW
    Bone Marrow Transplant; 1992 Oct; 10(4):391-5. PubMed ID: 1422499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
    Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
    Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    van Rhee F; Szydlo RM; Hermans J; Devergie A; Frassoni F; Arcese W; de Witte T; Kolb HJ; Niederwiser D; Jacobsen N; Gahrton G; Bandini G; Carreras E; Bacigalupo A; Michallet M; Ruutu T; Reiffers J; Goldman JM; Apperley J; Gratwohl A
    Bone Marrow Transplant; 1997 Oct; 20(7):553-60. PubMed ID: 9337056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results.
    Gaziev D; Galimberti M; Polchi P; Angelucci E; Giardini C; Baronciani D; Andreani M; Persini B; Erer B; Sodani P; Manna M; Nicolini G; Visani G; Lucarelli G;
    Bone Marrow Transplant; 2002 Jan; 29(1):1-8. PubMed ID: 11840137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.